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4 Observational research is critical to inform guidelines, policy, and the practice of HIV service 
5 delivery.1 The COVID-19 pandemic has profoundly affected healthcare systems and health behaviors 
6 world-wide, including at clinics and research sites that undergird global observational HIV research.2 
7 We consider the impact of the COVID-19 pandemic on the capture of relevant HIV data, indicator 
8 fidelity, and analytic approaches when investigating effects of COVID-19 itself or accounting for 
9 COVID-related changes in service delivery and care-seeking.
10
11 Data Sources
12 Observational HIV research relies on robust data sources that accurately reflect the delivery of routine 
13 patient care, which is the underlying data-generating mechanism. Due to the COVID-19 pandemic, 
14 patient health behaviors and HIV clinical care models have changed. Patients may be unable to attend 
15 clinic due to COVID-19 health concerns, reduced transportation, and stay-at-home orders. Clinics 
16 globally have responded with increased remote interactions through telehealth, electronic patient 
17 portals, social media platforms, and text and email messaging, as well as decentralized antiretroviral 
18 treatment (ART) delivery. 
19
20 However, new types of care and medication delivery may not be recorded consistently in paper or 
21 electronic health record systems and many providers working off-site may not have access to those 
22 systems for documentation.2,3 Even if these interactions are recorded, data may be inaccessible to 
23 researchers if stored in new systems or data fields.4 Linked data sources such as pharmacy systems 
24 may also experience changes in data quality and content, as prescriptions are dispensed in batches for 
25 community delivery or transferred to pharmacies offering reduced-contact dispensing.2,3  Mortality 
26 and other registries may experience data entry delays due to reporting delays and reduced staffing. 
27 These pandemic-related changes are likely to be as heterogeneous across the globe as the pandemic 
28 itself, disrupting the data sources researchers have used to assess trends in key HIV-related outcomes, 
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30
31 Indicators & Measurement
32 The HIV care continuum has become the preferred framework for understanding individual 
33 movement through various stages of HIV care, from testing and linkage to care, to retention in care, 
34 ART receipt, and ultimately, viral suppression. Barriers at various stages of the continuum have been 
35 conceptualized as “leaks,” with gaps, delays, and transitions out of care seen as undesirable events 
36 that should be mitigated through intervention.5,6 
37
38 HIV testing, diagnosis, and linkage to care have been delayed due to suspension or limitation of 
39 testing programs during mandatory public quarantine or social distancing measures. Outpatient clinic 
40 visits have been shifted to remote encounters when possible, and non-urgent care has been 
41 postponed.2,7 Individuals that appear to be lost to follow-up at their usual site of care may be seeking 
42 care elsewhere and medical records may not travel with them. Delays in ART initiation and refills 
43 have occurred due to loss of insurance, limited pharmacy dispensing capabilities, and/or limited 
44 outpatient activities. CD4 and viral load monitoring – central to HIV care – may also be delayed due 
45 to less available phlebotomy services or co-opting of equipment for COVID-related testing.3  
46
47 Both improved data capture and alteration of care continuum metrics may therefore be required to 
48 assess the extent of care/service disruptions and reduce measurement error and misclassification.8 
49 More sensitive definitions of engagement and retention accounting for non-traditional interactions 
50 may also be warranted. Many current retention metrics require clinical interactions every 3-6 months, 
51 but individuals successfully managed on ART and virally suppressed may need less frequent visits.6,9 
52 A conditional retention measure, based on ART receipt and viral suppression prior to clinic service 
53 disruption or upon return to clinic, may therefore be more informative about the care continuum than 
54 attended or even missed visit counts alone. For example, we could redefine retention status such that 
55 an individual would be successfully retained if they were virally suppressed and receiving ART both 
56 before local social isolation measures were imposed and after return to the clinic. Such a measure 
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62 In addition to changes in data collection and measurement during study design and conduct, we will 
63 also need to use analytic approaches that address the potential for artifactual temporal changes in HIV 
64 indicators due to COVID-19, selection biases, and measurement errors in the data-generating 
65 mechanisms of the care continuum. If patients attending telehealth visits are not representative of the 
66 entire cohort, if outcomes are unreliably ascertained among those lost to care, if certain measures are 
67 self-reported remotely instead of being collected on-site, or if discontinuities such as disruptions in 
68 care persist, appropriate epidemiologic and biostatistical methods such as inverse probability 
69 weighting, multiple imputation, double-sampling, and regression calibration should be considered.10–
70 12 To facilitate longer-term trend assessments which span the COVID-19 pandemic, analyses should 
71 also accommodate maximum flexibility, for example, through the use of restricted cubic splines, 
72 piecewise regression, or parametric mixture models.13,14 We must continue to assess the local clinical 
73 context to obtain more information relevant to HIV care changes induced by the COVID-19 pandemic 
74 and inform these approaches.15
75
76 Conclusion
77 Future HIV-related studies and public health goals require a new COVID-19-informed paradigm for 
78 the collection and use of observational cohort data. HIV cohorts must capture pandemic-driven 
79 changes in data sources, clinic activities, and local policies to inform analyses. Our ability to leverage 
80 epidemiologic evidence to inform clinical, programmatic, and public health practice is only as strong 
81 as the inferences derived from these analyses are valid and robust to the challenges in HIV care and 
82 research that we now face due to the pandemic. Healthcare organizations and public health agencies 
83 should revise HIV care continuum measures and analytic strategies. Funding for such work is critical, 
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